Send to printer »

GEN News Highlights : Mar 27, 2009

La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates

Preclinical flu and arenavirus vaccines will be coupled with DepoVax technology.

ImmunoVaccine Technologies (IVT) signed an agreement with the La Jolla Institute for Allergy & Immunology to test the application of its DepoVax™ vaccine delivery system for influenza and arenavirus vaccines.

The institute’s epitope-based vaccines are in preclinical research. The goal is that using DepoVax, only one vaccine dose will be required for protective immunity and that a strong cellular and humoral response is achieved.

DepoVax uses liposomes to encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that enhances vaccine induced cell-mediated and humoral immunity, according to IVT.